Best Peptides for Tissue Repair — Evidence Review
Tissue repair is the use case that drives most peptide community discussion. BPC-157 and TB-500 carry hundreds of animal-model studies between them. The human evidence is thin. The gap matters.
Tissue repair is the use case that drives most peptide community discussion. BPC-157 and TB-500 carry hundreds of animal-model studies between them. The human evidence is thin. The gap matters.
Peptides with the largest animal-model case
BPC-157
Over 200 published animal studies covering tendon, ligament, muscle, gut, bone, and nerve repair. Mechanism includes growth-factor modulation, FAK-paxillin pathway activation, nitric-oxide system action, and angiogenesis-related effects.
Zero completed human clinical trials. The animal-to-human translation gap is the central caveat. Pro-angiogenic profile means cancer history is a hard contraindication.
TB-500 (Thymosin Beta-4 fragment)
Tissue-repair animal-model evidence with a different mechanism than BPC-157 — actin sequestration affecting cell migration in repair contexts. Used in veterinary medicine for tendon and ligament injury in horses. Human research data is limited.
WADA prohibited substance.
MGF (Mechano Growth Factor)
IGF-1 splice variant produced in muscle response to mechanical loading. Animal studies show muscle and tendon repair acceleration. Human therapeutic data is preliminary.
GHK-Cu
The most-evidenced topical wound-healing peptide. Multiple human studies in dermal wound healing and post-procedural skin repair. Mechanism includes copper-mediated growth-factor signaling and ECM remodeling.
For surface tissue repair (skin, post-procedure scars), GHK-Cu has more human data than systemic peptides.
Thymosin Beta-4 (parent compound of TB-500)
Some hair-related and dermatologic research interest. Less common than the TB-500 fragment in research-use community discussion.
Full thymosin beta-4 profile →
Practical considerations
For tendon, ligament, and joint injury — orthopedic evaluation, structured rehabilitation, and time are the foundation. Peptide therapy is at best adjunctive to a clear diagnosis.
Pre-surgical use of pro-angiogenic peptides should be paused in advance of scheduled procedures (community protocols recommend 1–2 weeks washout). Coordinate with the surgical team.
Cancer-history patients should be cautious — pro-angiogenic peptides theoretically affect tumor biology in concerning directions.
What the evidence does not support
- BPC-157 or TB-500 as "cartilage regrowth" — no human osteoarthritis controlled-trial data
- "Cocktail protocols" combining 3+ injectable repair peptides without published combination evidence
- Use during active cancer treatment without oncology coordination
- Use as substitute for proper orthopedic or rehabilitation care
Where to source
- BPC-157 vendor rankings — 12 ranked vendors
- TB-500 vendor rankings — data aggregating
- GHK-Cu vendor rankings — 14 ranked vendors
Vendor variability for BPC-157 is notable: top-ranked vendors deliver ≥99.0% purity on independent HPLC; bottom-ranked vendors have shown both purity gaps and quantity divergence (vials labeled 5 mg containing 2–3 mg actual).
What we don't know
- Whether BPC-157 produces clinically meaningful improvement in any human tissue-repair indication
- Optimal dosing — community protocols extrapolate from rodent doses, which may not translate
- Long-term cancer-relevant safety in repeated users
- Whether oral or injectable BPC-157 produces better outcomes for specific indications
Methodology
Read the full methodology.
This page is educational. Tissue-repair concerns warrant proper diagnosis. Peptide therapy is at best adjunctive to a treating clinician's plan.